NicOx Press Releases
  Print
  Title (click to read)
Date
• NicOx to close US headquarters
04/08/2010
• NicOx first half 2010 financial results
30/07/2010
• FDA provides Complete Response Letter to NicOx's New Drug Application for naproxcinod
22/07/2010
• Presentation of preclinical data for NicOx's ophthalmology candidate NCX 434
28/06/2010
• NicOx: Presentation at ESH congress
22/06/2010
• NicOx: Presentations at EULAR congress
21/06/2010
• NicOx: Presentation of promising preclinical results in the fields of ophthalmology and pain
01/06/2010
• NicOx provides strategic update
19/05/2010
• NicOx provides update on FDA Advisory Committee Meeting for naproxcinod
13/05/2010
• Posting of Briefing Documents for FDA Advisory Committee on NicOx's naproxcinod - Company to host conference calls on Thursday May 13
11/05/2010
• NicOx reports first quarter 2010 financial results
07/05/2010
• Pooled phase 3 blood pressure results for NicOx's naproxcinod presented at the American Society of Hypertension (ASH)
03/05/2010
• NicOx: Publication of naproxcinod phase 3 data in Osteoarthritis and Cartilage
22/03/2010
• NicOx announces FDA Advisory Committee to discuss naproxcinod on May 12
08/03/2010
• NicOx 2009 Financial Results
04/03/2010
• NicOx and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116
03/03/2010
• NicOx announces EMEA validation of naproxcinod MAA submission
22/01/2010
• NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis
12/01/2010
• NicOx submits naproxcinod MAA to the EMEA
22/12/2009
• NicOx announces FDA accepts naproxcinod NDA for filing
18/11/2009
• NicOx announces NCX 6560 meets primary and secondary objectives in first-in-man study
13/11/2009
• Report of NicOx’s financial results for the first three quarters of 2009
22/10/2009
• NicOx presents 26 week naproxcinod efficacy data at American College of Rheumatology
20/10/2009
• NicOx submits New Drug Application (NDA) for naproxcinod to the US FDA
25/09/2009
• Important data for NicOx’ naproxcinod published in the American Journal of Cardiology
22/09/2009
• NicOx makes three scientific presentations at the 2009 World Congress on Osteoarthritis
14/09/2009
• NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer
06/08/2009
• NicOx first half 2009 financial results: naproxcinod nearing regulatory submissions in US and Europe
29/07/2009
• NicOx: additional 24 hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension
15/06/2009
• NicOx presents naproxcinod results in several posters at EULAR
12/06/2009
• NicOx publishes results of the ZEST phase 2 study for naproxcinod
09/06/2009
• NicOx presents phase 3 quality of life data for naproxcinod at ISPOR
19/05/2009
• NicOx reports first quarter 2009 financial results
13/05/2009
• Analyses of phase 3 blood pressure data for NicOx’ naproxcinod presented at ASH
07/05/2009
• NicOx co-presents four posters on PF 03187207 for glaucoma at ARVO with Pfizer Inc
05/05/2009
• NicOx acquires Nitromed’s NO-donating patents
23/04/2009
• New analyses of phase 3 data for NicOx’ naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting
31/03/2009
• NicOx initiates proof-of-principle clinical study for NCX 6560
18/03/2009
• Financial results for full year 2008: NicOx in a unique position to deliver significant shareholder value
26/02/2009
• NicOx announces results for TPI 1020 in COPD
23/12/2008
• NicOx’ naproxcinod shows differentiated 24-hour blood pressure profile after 13 weeks treatment
19/12/2008
• NicOx’ naproxcinod shows robust blood pressure results in phase 3 pooled analysis
17/12/2008
• NicOx signs agreement with DSM for the commercial manufacture of naproxcinod drug substance
02/12/2008
• Third pivotal phase 3 study for NicOx’ naproxcinod shows positive efficacy, safety and blood pressure results
24/11/2008
• NicOx’ naproxcinod shows highly significant reduction in daytime blood pressure versus naproxen
12/11/2008
• NicOx announces favorable blood pressure data for naproxcinod in a large ABPM study
04/11/2008
• NicOx reports results for the first three quarters of 2008
22/10/2008
• NicOx signs agreement with Capsugel for the commercial manufacture of naproxcinod oral capsules
23/09/2008
• NicOx announces second naproxcinod pivotal phase 3 study (302) meets efficacy primary endpoints and supports non-detrimental blood pressure effect
15/09/2008
• NicOx provides update on PF-03187207 and the ongoing research collaboration with Pfizer
25/08/2008
• First half 2008 financial results: NicOx nears completion of phase 3 naproxcinod studies
28/07/2008
• NicOx announces top-line results from naproxcinod 52-week 301 safety extension
24/07/2008
• NicOx completes enrollment of two Ambulatory Blood Pressure Measurement (ABPM) studies for naproxcinod in hypertensive OA patients
22/07/2008
• NicOx announces blood pressure analysis from 301 phase 3 study for naproxcinod at EULAR
13/06/2008
• NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study
28/05/2008
• NicOx announces departure of Damian Marron for CEO position
27/05/2008
• NicOx reports first quarter 2008 financial results
14/05/2008
• NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc.
13/05/2008
• NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
06/05/2008
• NicOx signs agreement for the commercial manufacture of naproxcinod drug substance
19/03/2008
• Financial results for full year 2007: NicOx significantly advances clinical programs
03/03/2008
• NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis
03/03/2008
• NicOx signs extension of ophthalmology agreement with Pfizer
08/01/2008
• NicOx announces Pfizer initiates phase 2 clinical development for PF-03187207 in Japan
03/01/2008
• NicOx completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update
14/12/2007
• NicOx announces TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020
20/11/2007
• NicOx’ naproxcinod phase 3 results presented at American College of Rheumatology
12/11/2007
• NicOx’ naproxcinod ABPM data presented at American Heart Association
07/11/2007
• NicOx reports results for the first nine months of 2007
29/10/2007
• NicOx opens US headquarters in New Jersey
15/10/2007
• NicOx and Ferrer present promising clinical and preclinical results in dermatology
02/10/2007
• NicOx reports TOPIGEN to advance TPI-1020 into phase 2 for COPD following promising clinical results
11/09/2007
• First half 2007 financial results: NicOx strengthens balance sheet and advances naproxcinod
30/07/2007
• NicOx receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic
16/07/2007
• NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
02/07/2007
• NicOx initiates third pivotal naproxcinod phase 3 study
29/06/2007
• NicOx provides an update on NCX 4016
18/06/2007
• NicOx provides an update on the phase 2a study for NCX 1000 conducted with Axcan
11/05/2007
• NicOx reports first quarter 2007 financial results
11/05/2007
• NicOx recruits Sanjiv Sharma as Vice President Commercial Affairs in the United States
30/04/2007
• NicOx initiates second phase 3 study to confirm naproxcinod’s efficacy and improved blood pressure profile
03/04/2007
• NicOx announces that Pfizer has disclosed further details of glaucoma trial for PF-03187207
29/03/2007
• Clinical development initiated on lead compound in NicOx’ glaucoma collaboration with Pfizer
28/03/2007
• NicOx’ 2006 financial results reflect a successful year of strong achievements and value creation
01/03/2007
• NicOx announces the success of its €130 million rights issue
14/02/2007
• NicOx presents promising pre-clinical results on an NO-donating latanoprost derivative from its glaucoma collaboration with Pfizer
12/02/2007
• NicOx announces the terms of its rights issue to advance naproxcinod and broader pipeline
29/01/2007
• NicOx launches a €130 million rights issue to advance naproxcinod and broader pipeline
22/01/2007
• NicOx receives €5 million milestone payment from Merck & Co. for antihypertensive collaboration
18/01/2007
• NicOx ABPM trial shows favorable blood pressure profile for naproxcinod
08/12/2006
• NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc.
14/11/2006
• NicOx receives FDA feedback that no cardiovascular outcomes study required for naproxcinod NDA
10/11/2006
• NicOx naproxcinod phase 3 OA trial meets primary endpoints and shows encouraging blood pressure profile
27/10/2006
• NicOx confirms the EMEA agrees with its proposed naproxcinod safety database
17/10/2006
• NicOx gives full details of naproxcinod phase 3 plan in osteoarthritis and an update on other R&D programs
06/09/2006
• NicOx selects NCX 6560 for development - a new statin with broadened cardiovascular benefit
06/09/2006
• NicOx completes enrolment ahead of schedule in ABPM trial for naproxcinod in hypertensive subjects
03/08/2006
• Strong operational and financial achievement mark a transforming six months for NicOx
26/07/2006
• NicOx to move NCX 4016 forward in phase 2 for diabetes
26/07/2006
• NicOx announces patient enrolment ongoing in NCX 1000 phase 2 study
22/06/2006
• NicOx receives WHO acceptance of naproxcinod as generic name for HCT 3012, first in new class of treatments for osteoarthritis
19/06/2006
• NicOx announces €15 million equity investment by Pfizer
02/06/2006
• NicOx completes enrolment of phase 3 trial for HCT 3012 in osteoarthritis ahead of schedule
24/05/2006
• NicOx partner Topigen initiates phase 2 program for TPI-1020 in respiratory disorders
23/05/2006
• NicOx and Ferrer select candidate for development in dermatology collaboration
16/05/2006
• NicOx initiates new trial to establish HCT 3012 as osteoarthritis treatment with beneficial blood pressure profile
04/05/2006
• NicOx announces fund raising of € 45.5 million by private placement
28/04/2006
• NicOx S.A. and Merck & Co., Inc. sign major exclusive worldwide agreement in antihypertensive field
21/03/2006
• NicOx signs major new agreement with Pfizer for NO-donating compounds in ophthalmology
02/03/2006
• NicOx compound demonstrates excellent preclinical results in Pfizer glaucoma collaboration
02/03/2006
• NicOx 2005 financial results: strong revenue growth and solid progress with clinical programs and partnerships
01/03/2006
• NicOx announces initiation of phase 3 trial for HCT 3012 in osteoarthritis
20/12/2005
• NicOx announces Pfizer's exercise of option to developp lead compound from ophthalmology collaboration
22/11/2005
• NicOx appoints PRA International - phase 3 program for HCT 3012 to be initiated
17/11/2005
• NicOx announces presentation of NCX 4016 phase 2a results in type 2 diabetes at American Heart Association
16/11/2005
• NicOx announces results of a phase 2 trial for NCX 4016 in PAOD
14/11/2005
• Merck & Co., Inc. and NicOx extend Research Collaboration
02/11/2005
• NicOx and Topigen sign agreement for NCX 1020 in COPD and other respiratory diseases
27/10/2005
• NicOx and Ferrer expand collaboration in dermatology
15/09/2005
• NicOx reports first-half results and provides a corporate update
28/07/2005
• NicOx announces important progress in Ophthalmology collaboration with Pfizer
21/07/2005
• Clinical trial shows promise with NicOx nitric oxide-donating compound in bone disease
11/07/2005
• NicOx completes expansion of R&D organization
06/07/2005
• NicOx announces the appointment of Dr. Ali Raza as Head of R&D
14/06/2005
• NicOx strengthens Development Team: Staffan Strömberg appointed VP Drug Development
01/06/2005
• NicOx receives second payment under Pfizer Research, Option, Development and Licensing agreement
30/03/2005
• NicOx' NCX 1020 achieves promising results in phase IIa for asthma
15/03/2005
• NicOx announces NCX 4016 more effective than aspirin at preventing platelet activation in diabetes in phase IIa study
01/03/2005
• NicOx reports 2004 financial results
01/03/2005
• NicOx NCX 1510 partnered with Biolipox demonstrates rapid relief in new clinical trial
22/02/2005
• NicOx selected to join European Community Network of Excellence, EICOSANOX
14/02/2005
• NicOx announces full patients enrollment in phase II trial of NCX 4016 in PAOD
20/01/2005
• Dr. Göran Ando joins NicOx Board of Directors
21/12/2004
• NicOx to proceed with phase III development of lead CINOD HCT 3012 following positive end phase II meeting with FDA
15/12/2004
• NicOx announces successful fund raising of 26 million euros by private placement
30/09/2004
• NicOx initiates clinical study to evaluate HCT 3012 effects on blood pressure vs.rofecoxib
08/09/2004
• NicOx, Pfizer sign Research, Option, Development and Licensing Agreement
26/08/2004
• NicOx reports first-half 2004 financial results
28/07/2004
• NicOx’s HCT 3012 shows equivalent efficacy to rofecoxib without any increase of Systolic Blood Pressure in osteoarthritis patients
10/06/2004
• NicOx informs: NCX 1510 successfully achieves primary endpoint in clinical Phase II trial in rhinitis
02/06/2004
• Nicox forms strategic alliance with Ferrer in dermatology - Promising Phase II clinical efficacy results announced for lead compound NCX 1022.
29/04/2004
• NicOx’s Alzheimer drug candidate shown to reduce key component of Alzheimer’s Disease
14/04/2004
• NicOx reports year-end 2003 financial results
26/02/2004
• NicOx announces positive evaluation of overall phase II clinical results on AZD3582 by a U.S. Consultant Advisory Board.
27/01/2004
• First NicOx compound in Biolipox collaboration enters phase II
21/01/2004
• NCX 4016 successfully achieves primary efficacy endpoint in Phase II clinical study of symptomatic peripheral arterial obstructive disease (PAOD)
08/01/2004
• NicOx to reacquire to CINOD class of drugs from AstraZeneca
23/09/2003
• NicOx: Clinical study with NCX 4016 showing nitric oxide protects against aspirin-induced gastric damage to be presented at AHA meeting.
09/09/2003
• Merck & Co., Inc. and NicOx form research collaboration on Nitric Oxide-donating drugs
19/08/2003
• NicOx reports first-half 2003 financial results
24/07/2003
• NicOx: Successful Phase II efficacy results with NCX 701 in acute pain
18/06/2003
• Clinical results show NicOx's NCX 4016 maintains excellent gastric safety in co-administration with celecoxib
21/05/2003
• NicOx announces successful Phase I clinical results with HCT 1026 in development for Alzheimer's disease.
13/05/2003
• NicOx: NCX 1020 begins clinical development in respiratory disease
01/04/2003
• Further update on AZD3582 following meeting of independent Panel
26/03/2003
• NicOx announces National Cancer Institute grant for a human clinical trial of NCX 4016 in prevention of colon cancer
13/03/2003
• NicOx announces preliminary review of data from Phase II study of AZD3582
11/03/2003
• NicOx reports year-end 2002 financial results
03/03/2003
• NicOx has requested an investigation from the "Commission des Opérations de Bourse".
24/02/2003
• NicOx requests full data file on AZD3582
20/02/2003
• NicOx: Research Update on NicOx
18/02/2003
• NicOx and Axcan granted US IND for Phase I clinical studies on NCX 1000
05/02/2003
• NicOx and Biolipox expand research collaboration on novel nitric oxide-donating compounds for the treatment of respiratory diseases.
29/01/2003
• Jean-Luc Bélingard, President and CEO of Beaufour-Ipsen, joins NicOx Board of Directors
13/12/2002
• AZD4717 selected as second lead compound from CINOD class by AstraZeneca et NicOx
07/11/2002
• NicOx informs: Positive Phase II clinical data in acute pain presented on AZD3582
07/11/2002
• NicOx granted US IND for Phase II trials with NCX 4016 in cardiovascular diseases
24/10/2002
• NicOx signs Exclusive Agreement with AstraZeneca for the development of AZD3582 and other CINOD in Japan
30/09/2002
• NicOx granted US IND for Phase II clinical testing of NCX 701 in acute pain
17/09/2002
• NicOx reports first half 2002 financial results
25/07/2002
• NicOx announces first clinical results for inhaled NCX 950 in respiratory diseases
08/07/2002
• NicOx announces a three-for-one stock split.
14/06/2002
• NicOx's HCT 3012 shows equivalent efficacy to rofecoxib without any increase of Systolic Blood Pressure in osteoarthritis patients
10/06/2002
• NicOx and Axcan sign co-development and license agreement for NCX 1000 in the treatment of chronic liver diseases
23/05/2002
• NicOx's Nitric Oxide-donating Aspirin is Safe for the Gastrointestinal Tract in Humans.
22/05/2002
• NicOx informs: first gastrointestinal data presented on AZD3582, the first of a potential new class of pain medications.
21/05/2002
• NicOx appoints Sylvain Goyon as Director of Corporate Relations
14/05/2002
• NicOx provides an update on the phase 2a study for NCX 1000 conducted with Axcan
11/05/2002
• Positive Phase I/IIa clinical results for nitric oxide-donating aspirin showing novel inhibition of vascular inflammation and platelet activation
16/04/2002
• NicOx appoints Damian Marron as Senior Director, Business Development
13/03/2002
• NicOx announces NCX 4016 more effective than aspirin at preventing platelet activation in diabetes in phase IIa study
01/03/2002
• NicOx reports year end 2001 financial results
22/02/2002
• NicOx NCX 1510 partnered with Biolipox demonstrates rapid relief in new clinical trial
22/02/2002
• NicOx announces positive Phase I results and new pre-clinical data on NCX 1015
14/02/2002
• NicOx granted IND status for clinical testing of HCT 1026 in the US
07/01/2002
• NicOx announces start of pilot Phase II trial for NO-aspirin in treatment of insulin resistance and associated vascular impairments after promising preclinical data
14/11/2001
• Promising preclinical results for new NO-releasing compounds
27/09/2001
• NicOx Research Center opens in northern Italy
19/09/2001
• NicOx reports first half 2001 financial results
26/07/2001
• NicOx's NO-releasing chemopreventive agents receive second research grant from U.S. National Cancer Institute
09/07/2001
• Vaughn M. Kailian, President and CEO of COR Therapeutics Inc., joins NicOx Board of Directors
02/07/2001
• NicOx: positive Phase I clinical results for the first administration into man of NCX 701
27/06/2001
• NicOx and Biolipox enter into research collaboration
25/06/2001
• NicOx's Nitric Oxide-Releasing Steroid, NCX 1022, Shows Promising Clinical Results in Skin Blanching
14/05/2001
• NicOx's HCT 1026 shows positive clinical dermatology results in prolonged contact urticaria
18/04/2001
• Publication in Proceedings National Academy of Sciences of USA (PNAS) shows new cell proliferation inhibitory properties by Nitric Oxide donors
27/03/2001
• Financial results 2000 - NicOx reports increased revenues and decreased net loss
08/03/2001
• Frank Baldino, Chairman and CEO of Cephalon Inc., joins NicOx Board of Directors
08/03/2001
• Publication in the Proceedings National Academy of Sciences of USA (PNAS) reports that NCX-4016 reduces restenosis in vivo
27/02/2001
• NO-aspirins inhibit human colon and pancreatic cancer cell growth in vitro
08/02/2001
• NicOx's HCT-3012 advances into Phase II Human Clinical Trials. Company receives US$ 3 million Milestone Payment from AstraZeneca
24/01/2001
• Three NicOx drug candidates advance into phase I clinical trials
18/12/2000
• NicOx presents positive preclinical data on anti-inflammatory and neuroprotective effects of NCX-2216
11/12/2000
• HCT 1026 shows positive clinical results in the treatment of skin inflammation
28/11/2000
• NO-Aspirin (NCX 4016) effective in preventing vein graft failure in animal models
21/11/2000
• NCX-4016 reduces myocardial infarct size in anaesthetised pigs subjected to ischaemia / reperfusion
20/10/2000
• NicOx announces National Cancer Institute research grant to study cancer prevention with its NO-releasing chemopreventive agents.
21/09/2000
• NicOx reports first half 2000 financial results
31/07/2000
• Preclinical results announced for Alzheimer’s drug, NCX 2216. Data presented at the 7th International Conference on Alzheimer’s Disease and Related Disorders in Washington DC.
19/07/2000
• NicOx announces positive preliminary phase I/II results in contact urticaria. Commences second dermatology study.
03/07/2000
• NicOx announces positive pre-clinical results for NO-paracetamol (NCX 701)
09/06/2000
• NicOx announces positive pre-clinical results in liver disease with NCX 1000 presented at the American Gastroenterological Association Congress in San Diego.
25/05/2000
• NicOx receives Milestone Payment from AstraZeneca for initiation of Phase 1 Trial of HCT-3012
19/05/2000
• HCT 1026: Advancement of clinical trials in overactive bladder Encouraging phase II preliminary results in neurogenic bladder
12/05/2000
• NicOx Granted CTX for HCT-1026 by UK Medicines Control Agency in urinary incontinence
20/04/2000
• NicOx reports year end 1999 financial results
20/03/2000
• NicOx initiates human clinical trials in dermatology with HCT-1026
15/03/2000
• New oral formulation of NCX 4016 (NO-aspirin) Initiates Phase I Clinical trials in France.
21/02/2000
• NicOx granted IND by US Food and Drug Administration for NCX 4016 (NO-aspirin)
27/01/2000
• NicOx initiates Phase II trial with HCT-1026 in Paget’s disease
20/12/1999
• NicOx S.A. Lists On French Nouveau Marché
03/11/1999
• NicOx amends structure of its Nouveau Marché Initial Public Offering
27/10/1999
• NicOx, leader in the development of nitric oxide-releasing drugs, announces its intention to list its shares on the Paris Stock Exchange "Nouveau Marché"
11/10/1999
• NicOx initiates Phase II trial with HCT-1026 for urinary incontinence
26/07/1999
• NicOx awarded 1998 AFIC Prize for Innovation
09/12/1998
• NicOx Makes Two New Board Members Appointments
30/11/1998
• Nobel Prize for Research on Nitric Oxide, awarded to a Member of the Scientific Advisory Board of NicOx S.A.
13/10/1998
• NicOx Signs Exclusive Licence Agreement for NO-NSAIDs with Astra
02/10/1998
• NicOx appoints Professor Salvador Moncada to Board of Directors
27/03/1998
• Bayer and NicOx enter into research collaboration
05/03/1998
• NicOx S.A. completes private placement financing
15/12/1997
• NicOx completes phase I clinical trial in UK of its anti-inflammatory HCT-1026. Patents granted in US and Europe covering HCT-1026.
25/04/1997
• NicOx’s lead anti-inflammatory drug candidate HCT-1026 advances in development
05/12/1996
• NicOx starts phase I clinical trials of its anti-thrombotic NCX-4016 in UK.
08/10/1996
  Print